Hearing loss prevention pill put to the test — but study never started

NCT ID NCT02779192

Terminated Prevention Sponsor: Sound Pharmaceuticals, Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to test whether an oral drug called SPI-1005 (ebselen) could prevent temporary hearing loss caused by loud noise. Researchers planned to enroll adults aged 18-50 with a history of noise exposure and give them the drug or a placebo for 7 days, then measure hearing changes after a controlled sound challenge. However, the trial was withdrawn before any participants were enrolled, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPI-1005 (ebselen)
What this could lead to: If it works, this could point toward a pill that protects against hearing loss from loud noise.
What could go wrong: The study was withdrawn before enrolling anyone, so no results exist. It is unclear if the drug is effective or safe for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NOISE-INDUCED HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

noise induced hearing loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NOISE-INDUCED HEARING LOSS

Contacts and locations

Locations

MUSC

Charleston, South Carolina, 29425, United States
Sound Pharmaceuticals, Inc.

Seattle, Washington, 98103, United States
University of Kansas Medical Center

Kansas City, Kansas, 66103, United States
University of Miami

Miami, Florida, 33136, United States
University of Texas Southwestern

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.